

- **Name:** Jee Hyun Kim
  - **Current Position & Affiliation:** Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine
  - **Country:** Republic of Korea
- 

**• Educational Background:**

- 2002 – 2004 Ph.D. in Internal Medicine, Seoul National University, Graduate School,
- 2000 – 2002 M.S. in Internal Medicine, Seoul National University, Graduate School
- 1989 – 1995 M.D. degree from Seoul National University College of Medicine, Republic of Korea
- 2001-2002 Fellowship in Division of Hematology-Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Republic of Korea
- 1997-2001 Residency in Department of Internal Medicine, Seoul National University Hospital, Republic of Korea
- 1995-1996 Internship in Seoul National University Hospital, Republic of Korea

**• Professional Experience:**

- 2019 – current: Director, Precision Medicine Center, Seoul National University Bundang Hospital
- 2017- 2020: Director, Clinical Trial Center, Seoul National University Bundang Hospital
- 2015- current: Professor, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Republic of Korea
- 2011-2016: Chief, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital
- 2009-2015: Associate Professor, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Republic of Korea
- 2008-2009: Visiting professor, Division of molecular and cellular oncology, Department of Medical Oncology, Dana Farber Cancer Institute, U.S
- 2005-2008: Assistant Professor, Seoul National University College of Medicine,
- 2003-2008: Assistant Professor, Seoul National University Bundang Hospital, Republic of Korea

**• Professional Organizations:**

- Leader, Korean Precision Medicine Networking Group
- Director without portfolio, Korean Society of Medical Oncology
- Chair, Education committee, Korean Cancer Study Group
- Board member, Korean Cancer Association
- Active member, American Society of Medical Oncology, American Association for Cancer Research, International Society of Geriatric Oncology

**• Main Scientific Publications:**

1. Yoon S, Kim M, Hong YS, Kim HS, Kim ST, Kim J, Yun H, Yoo C, Ahn HK, Kim HS, Lee

15<sup>th</sup> Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

- IH, Kim IH, Park I, Jeong JH, Cheon J, Kim JW, Yun J, Lim SM, Cha Y, Jang SJ, Zang DY, Kim TW, Kang JH, **Kim JH**. Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group. *Cancer Res Treat* 2022;54:1-9
2. **Kim JH**, Im SA, Sim SH, Bananis E, Huang X, Kim HS, Kim SB. Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. *J Breast Cancer* 2021 Feb;24(1):97-105.
  3. Lee HJ, Kim KJ, Sung JH, Nam M, Suh KJ, Kim JW, Kim SH, Kim JW, Kim YJ, Lee KW, Lee JS, **Kim JH**. PI3K p110 $\alpha$  Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells *Cancers (Basel)* 2020 Sep 3;12(9):2500.
  4. Kim SH, Ahn S, Suh KJ, Kim YJ, Park SY, Kang E, Kim EK, Kim IA, Chae S, Choi M, **Kim JH**. Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer. *Breast Cancer Res Treat.* 2020 Jul 26. doi: 10.1007/s10549-020-05811-2
  5. Hong S, Lee JH, Chun EK, Kim KI, Kim JW, Kim SH, Lee YG, Hwang IG, Kim JY, Koh SJ, Ko YH, Shin SH, Woo IS, Kim TY, Baek JY, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Ryoo HM, **Kim JH**. Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy. *Oncologist.* 2020 Mar;25(3):e502-e511
  6. Lee YG, Lee JH, Kim SH, Kim YJ, Lee H, Ahn S, Jang JS, Lee JS, **Kim JH**. Comparative analysis between combination and single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer: A nationwide population-based outcome study. *Lung Cancer.* 2018 Aug;122:88-93.
  7. Kim JW, Lee YG, Hwang IG, Song HS, Koh SJ, Ko YH, Shin SH, Woo IS, Hong S, Kim TY, Kim SY, Nam BH, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Bae SH, Koo DH, Kim KI, **Kim JH**. Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. *Br J Cancer.* 2018 May;118(9):1169-1175.
  8. Suh KJ, Kim SH, Lee KH, Kim TY, Kim YJ, Han SW, Kang E, Kim EK, Kim K, No JH, Han W, Noh DY, Lee M, Kim HS, Im SA, **Kim JH**. Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors. *Cancer Res Treat.* 2017 Oct;49(4):1153-1163.
  9. Kim SH, Jung KH, Kim TY, Im SA, Choi IS, Chae YS, Baek SK, Kang SY, Park S, Park IH, Lee KS, Choi YJ, Lee S, Sohn JH, Park YH, Im YH, Ahn JH, Kim SB, **Kim JH**. Prognostic Value of Axillary Nodal Ratio After Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide (AC) Followed by Docetaxel (DOC) in breast cancer: A Multicenter Retrospective Cohort Study. *Cancer Res Treat.* 2016 Oct;48(4):1373-1381.
  10. Kim JW, Kim SH, Kim YJ, Lee KW, Kim KI, Lee JS, Kim CH, **Kim JH**; Korean Cancer Study Group Geriatric Oncology Working Party. A Novel Geriatric Screening Tool in Older Patients with Cancer: The Korean Cancer Study Group Geriatric Score (KG)-7. *PLoS One* 2015;10(9):20138304.